Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Hackensack Meridian Health
Massachusetts General Hospital
Thomas Jefferson University
Children's Hospital Medical Center, Cincinnati
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
Celgene
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Rush University Medical Center
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
Burzynski Research Institute
Wake Forest University Health Sciences
Wake Forest University Health Sciences
NYU Langone Health
Northwestern University
M.D. Anderson Cancer Center
Massachusetts General Hospital
Northwestern University
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pediatric Brain Tumor Consortium
NYU Langone Health
Radiation Therapy Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Case Comprehensive Cancer Center
Eli Lilly and Company